Head-to-head · Cost-Efficiency Index
Joey Med vs NuBloom
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Joey Med
Shoppers who want to pick a molecule-agnostic 'Core / Plus Core' tier and pay per 4, 8, or 12 weeks rather than a recurring monthly subscription.
Visit Joey MedNuBloom
Cost-first shoppers who want a physician-founded, whole-person GLP-1 program for women, in the 49 states it publishes as covered.
Visit NuBloomThe verdict
Joey Med and NuBloom tie on the Cost-Efficiency Index at 54/100, so neither wins outright on the numbers. For most shoppers we'd start with Joey Med (ranked #356, a hair above #361) — Shoppers who want to pick a molecule-agnostic 'Core / Plus Core' tier and pay per 4, 8, or 12 weeks rather than a recurring monthly subscription. But NuBloom is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Joey Med.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Joey Med | NuBloom |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 54/100 |
| Semaglutide / mo | $199/mo (promotional rate, compounded) | Not disclosed |
| Tirzepatide / mo | $275/mo (promotional rate, compounded) | $249/mo (microdose tier, compounded) |
| Semaglutide / yr (modeled) | $2,388 | — |
| Tirzepatide / yr (modeled) | $3,300 | $2,988 |
| Coverage | All 50 states | 49 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #356 | #361 |
Joey Med
54/100Where the value is
- The site's own embedded pricing data is fully itemized by tier (4/8/12 weeks) for all three products
- Molecule names are disclosed on the category page even though individual product pages use branded tier names
- Legal entity is disclosed via the site's own structured data: MD Telehealth Platform LLC DBA Joey Med
The tradeoffs
- The current roster's prices were stale: $279 was the crossed-out list price for semaglutide (actual: $199), and $399 belonged to the High Dose tirzepatide tier, not the standard $275 entry tier
- Drug names are buried under branded tier names on the product pages themselves
NuBloom
54/100Where the value is
- Transparent, openly published starting pricing: semaglutide $149/mo, tirzepatide $279/mo, with a cheaper $249/mo microdose tirzepatide option
- Founded and medically led by a named, identifiable physician (Dr. Marianne Pinkston Mueller)
- Full state-coverage list published and independently countable: 49 states, all except Mississippi
The tradeoffs
- Compounding pharmacy partner is never named anywhere on the site — only 'a state-licensed sterile compounding pharmacy partner'
- NuBloom's own independent LegitScript status isn't distinctly confirmed; the certification language attaches to its telehealth-platform partner, Telegra
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.